Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Ontario Premier Kathleen Wynne said Wednesday her government will try to find out how watered down chemotherapy drugs were given to more than 1,100 cancer patients, some for as long as a year.

"It's a very worrisome situation, obviously most worrisome for the patients and their families involved, and we will work to find out how this happened," said Wynne.

"I don't know exactly how this happened, but we obviously need to find out how it happened."

Story continues below advertisement

Five hospitals — four in Ontario and one in New Brunswick — are contacting patients who received the too-low chemo doses to tell them to contact their oncologist to discuss treatment plans.

Questions have been raised about the impact the lower than intended doses of the chemotherapy drugs might have had on the treatment for the cancer patients and whether or not they could have lived longer with proper doses.

"What is the implication of that dilution? Does it mean it would affect the outcomes of people's treatment, their longevity," asked Ontario NDP Leader Andrea Horwath.

The provincial Health Ministry and Cancer Care Ontario have a lot of questions to answer, added Horwath.

"I think this rocks people's trust in the health care system and in the distribution of drugs in Ontario, and that's worrisome," she said.

"People need to be certain that the treatment they're receiving is the treatment that's prescribed and that it's the appropriate treatment for whatever illness or disease they happen to be battling."

The drug supplier, Marchese Hospital Solutions, said it is "deeply concerned" by the questions raised about the quality of its work and that it is addressing those issues.

Story continues below advertisement

"Our preliminary investigation of this issue leads us to be confident that we have met the quality specifications of the contract," the company said on its website.

A total of 990 patients treated or being treated at London Health Sciences Centre, Windsor Regional Hospital, Lakeridge Health in Oshawa and Peterborough Regional Health Centre are affected.

The Ontario patients received lower than intended doses of the drugs cyclophosphamide and gemcitabine, while the Saint John Regional Hospital in New Brunswick said 186 patients received watered down doses of cyclophosphamide.

The drugs were being used as far back as February 2012 at the Windsor hospital, and March 2012 at the London hospital. The Saint John hospital said it had purchased the drugs since March 2012.

Ontario Health Minister Deb Matthews said Tuesday that she doesn't want people to panic about the situation. She urged the affected patients to contact their oncologist.

Cancer Care Ontario said all four Ontario hospitals immediately removed the medications received from the drug manufacturer when the problem was discovered late last month, and informed Marchese of the error.

Story continues below advertisement

Each hospital has secured new supplies of the medications and Cancer Care Ontario said patients' treatment cycles will not be interrupted.

"It's important to note that chemotherapy preparation and delivery is a complex process and as a result of this complexity, there are sources for potential error," Dr. Carol Sawka, Cancer Care Ontario's vice-president of clinical programs and quality initiatives, said in a statement.

"We have put in many steps to minimize these potential sources of error and we will continue to ensure that patient safety and high quality care are the focus and the strength of the system."

The underdosing affected 665 patients at London Health Sciences Centre, 290 patients at Windsor Regional Hospital, 34 at Lakeridge Health, and one patient at Peterborough Regional Health Centre.

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies